Pirfenidone, a unique experimental drug with anti-fibrotic and anti-inflammatory properties, afforded no apparent therapeutic benefit in horses with experimentally-induced endotoxemia, leaving Cal Davis researchers rather disappointed.
"Previous studies led us to believe that pirfenidone would minimize the effects o
To continue reading this article, become a member of TheHorse.com.
It's FREE and you'll get full access to more than 20,000 articles, video, free reports & more.













